Everest Medicines signs US$1.14B licensing agreement for Civorebrutinib with Travere

CHINA— Everest Medicines has completed its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics for the development and commercialization of civorebrutinib, also known as EVER001.

The investigational therapy is a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor that will be developed for the U.S. and other global markets, excluding Greater China and selected countries in East and Southeast Asia.

The transaction officially closed this week after the companies first announced the partnership in early June.

Under the agreement, Everest Medicines will receive US$112.5 million upfront from Travere Therapeutics and could earn up to US$1.03 billion more in milestone payments if certain clinical, regulatory, and commercial goals are met across five indications.

In addition, Travere will pay tiered royalties on future sales in its licensed territories, with royalty rates ranging from high single-digit to double-digit percentages based on annual net sales.

Focus on kidney and autoimmune diseases

EVER001 is being developed as a next-generation BTK inhibitor for immune-mediated kidney diseases.

Through the agreement, Travere gains exclusive rights to develop and commercialize the therapy outside Greater China and selected Asian markets, while Everest retains rights in its core territories.

The companies expect the partnership to accelerate global clinical development and broaden access to the investigational treatment if it receives regulatory approval.

The latest agreement also strengthens Everest Medicines’ strategy of combining business development partnerships with internal research.

In recent months, the company has expanded its renal disease pipeline through several licensing agreements.

Its portfolio now includes MT1013, DMX-200 and Bejescin®, alongside its flagship kidney disease therapy, NEFECON®.

Together, these programmes target conditions such as IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis (FSGS), and complications linked to chronic kidney disease.

Recent pipeline expansion

The closing of the Travere agreement follows several other business development milestones for Everest Medicines.

In recent weeks, the company announced that China’s National Medical Products Administration accepted the biologics licence application for LEROCHOL®, its treatment for adults with hypercholesterolaemia.

It also signed commercialization and licensing agreements involving budesonide enteric capsules, DMX-200 and LNZ100, further expanding its pipeline in kidney and cardiovascular diseases.

For Everest Medicines, the completed transaction marks another step in its shift from relying mainly on in-licensed products to advancing medicines discovered through its own research.

The company said the progress of EVER001 highlights its growing research and development capabilities while supporting its broader strategy of building global partnerships for innovative therapies.